Search
Now showing items 1-1 of 1
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
(Elsevier, 2022-04-20)
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs)
for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed to ...